Skip to main content
Top
Published in: BMC Gastroenterology 1/2017

Open Access 01-12-2017 | Research article

The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors

Authors: Zhidong Gao, Chao Wang, Qian Xue, Jingtong Wang, Zhanlong Shen, Kewei Jiang, Kai Shen, Bin Liang, Xiaodong Yang, Qiwei Xie, Shan Wang, Yingjiang Ye

Published in: BMC Gastroenterology | Issue 1/2017

Login to get access

Abstract

Backgroud

The detectable rate of minimal gastric GISTs has continuously increased. While the surveillance and management of GIST <2 cm have been deemed controversial or lack evidence-based approaches.  The aim of the current study is to propose a cut-off value of tumor size for treatment policy and the appropriate timing for endoscopic ultrasonography (EUS) follow-up in the minimal EUS-suspected gastric GIST patients.

Methods

A single-institution retrospective study was performed. 69 patients with EUS-suspected gastric GISTs were studied from November 2008 to March 2015. 69 patients with minimal gastric GISTs ≤2 cm diagnosed by EUS were followed for a mean period of 29 months (range, 12 to 70). An at least 20% increase of the maximal diameter of the tumors was set as a significant change.

Results

During follow-up, Of the 69 minimal EUS-suspected GISTs, 16 (23.2%) showed significant changes in size. 11 out of 69 GISTs (15.9%), 6 out of 43 GISTs (14.0%), 7 out of 30 GISTs (23.3%) showed significant changes in size, at 1 year, 2 years, and more than 3 years respectively. The receiver operating characteristic curve analysis showed that the tumor size cut-off was 9.5 mm. Only 4.7 and 3.7% of gastric EUS-suspected GISTs of <9.5 mm in size showed significant changes at 1 year and 2 years, while 9.5% at more than 3 years. 34.6, 31.3 and 55.6% of gastric EUS-suspected GISTs of ≥ 9.5 mm in size showed significant changes at 1 year, 2 years and more than 3 years.

Conclusions

Minimal EUS-suspected GISTs, larger than 9.5 mm may be associated with significant progression. The patients with a ≥ 9.5 mm GIST should have a EUS 6–12months, while <9.5 mm GIST may have a EUS extended to every 2–3 years.
Appendix
Available only for authorised users
Literature
1.
go back to reference Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. Lancet oncol. 2012;13:265–74.CrossRefPubMed Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. Lancet oncol. 2012;13:265–74.CrossRefPubMed
2.
go back to reference Brand B, Oesterhelweg L, Binmoeller KF, et al. Impact of endoscopic ultrasound for evaluation of submucosal lesions in gastrointestinal tract. Dig liver dis. 2002;34:290–7.CrossRefPubMed Brand B, Oesterhelweg L, Binmoeller KF, et al. Impact of endoscopic ultrasound for evaluation of submucosal lesions in gastrointestinal tract. Dig liver dis. 2002;34:290–7.CrossRefPubMed
3.
go back to reference Rösch T, Kapfer B, Will U, et al. Accuracy of endoscopic ultrasonography in upper gastrointestinal submucosal lesions: a prospective multicenter study. Scand j gastroenterol. 2002;37:856–62.CrossRefPubMed Rösch T, Kapfer B, Will U, et al. Accuracy of endoscopic ultrasonography in upper gastrointestinal submucosal lesions: a prospective multicenter study. Scand j gastroenterol. 2002;37:856–62.CrossRefPubMed
4.
go back to reference Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer epidemiol. 2016;40:39–46.CrossRefPubMed Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer epidemiol. 2016;40:39–46.CrossRefPubMed
5.
go back to reference Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am j surg pathol. 2005;29:52–68.CrossRefPubMed Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am j surg pathol. 2005;29:52–68.CrossRefPubMed
6.
go back to reference Rossi S, Gasparotto D, Toffolatti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am j surg pathol. 2010;34:1480–91.CrossRefPubMed Rossi S, Gasparotto D, Toffolatti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am j surg pathol. 2010;34:1480–91.CrossRefPubMed
7.
go back to reference Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am j surg pathol. 2007;31:113–20.CrossRefPubMed Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am j surg pathol. 2007;31:113–20.CrossRefPubMed
8.
go back to reference Coe TM, Fero KE, Fanta PT, et al. Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA. J gastrointest surg. 2016;20:1132–40.CrossRefPubMed Coe TM, Fero KE, Fanta PT, et al. Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA. J gastrointest surg. 2016;20:1132–40.CrossRefPubMed
9.
go back to reference von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2016, NCCN clinical practice guidelines in oncology. J natl compr canc netw. 2016;14:758–86. von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2016, NCCN clinical practice guidelines in oncology. J natl compr canc netw. 2016;14:758–86.
10.
go back to reference Ando N, Goto H, Niwa Y, et al. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest endosc. 2002;55:37–43.CrossRefPubMed Ando N, Goto H, Niwa Y, et al. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest endosc. 2002;55:37–43.CrossRefPubMed
11.
go back to reference Akahoshi K, Sumida Y, Matsui N, et al. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration. World j gastroenterol. 2007;13:2077–82.CrossRefPubMedPubMedCentral Akahoshi K, Sumida Y, Matsui N, et al. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration. World j gastroenterol. 2007;13:2077–82.CrossRefPubMedPubMedCentral
12.
go back to reference Mekky MA, Yamao K, Sawaki A, et al. Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors. Gastrointest endosc. 2010;71:913–9.CrossRefPubMed Mekky MA, Yamao K, Sawaki A, et al. Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors. Gastrointest endosc. 2010;71:913–9.CrossRefPubMed
13.
go back to reference Palazzo L, Landi B, Cellier C, et al. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut. 2000;46:88–92.CrossRefPubMedPubMedCentral Palazzo L, Landi B, Cellier C, et al. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut. 2000;46:88–92.CrossRefPubMedPubMedCentral
14.
go back to reference Yang J, Feng F, Li M, et al. Surgical resection should be taken into consideration for the treatment of small gastric gastrointestinal stromal tumors. World j surg oncol. 2013;11:273.CrossRefPubMedPubMedCentral Yang J, Feng F, Li M, et al. Surgical resection should be taken into consideration for the treatment of small gastric gastrointestinal stromal tumors. World j surg oncol. 2013;11:273.CrossRefPubMedPubMedCentral
15.
go back to reference Lachter J, Bishara N, Rahimi E, et al. EUS clarifies the natural history and ideal management of GISTs. Hepatogastroenterology. 2008;55:1653–6.PubMed Lachter J, Bishara N, Rahimi E, et al. EUS clarifies the natural history and ideal management of GISTs. Hepatogastroenterology. 2008;55:1653–6.PubMed
16.
go back to reference Gill KR, Camellini L, Conigliaro R, et al. The natural history of upper gastrointestinal subepithelial tumors: a multicenter endoscopic ultrasound survey. J clin gastroenterol. 2009;43:723–6.CrossRefPubMed Gill KR, Camellini L, Conigliaro R, et al. The natural history of upper gastrointestinal subepithelial tumors: a multicenter endoscopic ultrasound survey. J clin gastroenterol. 2009;43:723–6.CrossRefPubMed
17.
go back to reference Kim MY, Jung HY, Choi KD, et al. Natural history of asymptomatic small gastric subepithelial tumors. J clin gastroenterol. 2011;45:330–6.CrossRefPubMed Kim MY, Jung HY, Choi KD, et al. Natural history of asymptomatic small gastric subepithelial tumors. J clin gastroenterol. 2011;45:330–6.CrossRefPubMed
18.
go back to reference Fang YJ, Cheng TY, Sun MS, et al. Suggested cutoff tumor size for management of small EUS-suspected gastric gastrointestinal stromal tumors. J formos med assoc. 2012;111:88–93.CrossRefPubMed Fang YJ, Cheng TY, Sun MS, et al. Suggested cutoff tumor size for management of small EUS-suspected gastric gastrointestinal stromal tumors. J formos med assoc. 2012;111:88–93.CrossRefPubMed
19.
go back to reference Sepe PS, Moparty B, Pitman MB, et al. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest endosc. 2009;70:254–61.CrossRefPubMed Sepe PS, Moparty B, Pitman MB, et al. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest endosc. 2009;70:254–61.CrossRefPubMed
20.
go back to reference Ha CY, Shah R, Chen J, et al. Diagnosis and management of GI stromal tumors by EUS-FNA: a survey of opinions and practices of endosonographers. Gastrointest endosc. 2009;69:1039–44.CrossRefPubMed Ha CY, Shah R, Chen J, et al. Diagnosis and management of GI stromal tumors by EUS-FNA: a survey of opinions and practices of endosonographers. Gastrointest endosc. 2009;69:1039–44.CrossRefPubMed
21.
go back to reference ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest endosc. 2015;82:1–8.CrossRef ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest endosc. 2015;82:1–8.CrossRef
Metadata
Title
The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors
Authors
Zhidong Gao
Chao Wang
Qian Xue
Jingtong Wang
Zhanlong Shen
Kewei Jiang
Kai Shen
Bin Liang
Xiaodong Yang
Qiwei Xie
Shan Wang
Yingjiang Ye
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2017
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-016-0567-4

Other articles of this Issue 1/2017

BMC Gastroenterology 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.